ASH 2023 | IFN-beta-1a for preventing toxicities after CD19-directed CAR T-cell therapy: a trial in progress
Emily Liang, MD, Fred Hutchinson Cancer Center, Seattle, WA, introduces a Phase I/II trial (NCT05936229) which will assess the safety, feasibility, and efficacy of intravenous (IV) interferon-beta-1a (IFN-beta-1a) in the prevention of toxicities associated with CD19-directed CAR T-cell therapy. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which are significant contributors to morbidity and mortality following CAR-T, occur as a result of increased vascular permeability and blood-brain barrier damage. Dr Liang explains the mechanism of action by which IFN-beta-1a may protect against this damage and outlines the primary and secondary study outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
